Key statistics
On Friday, Roche Holding AG (RHO6:BER) closed at 34.50, 9.52% above its 52-week low of 31.50, set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.30 |
---|---|
High | 35.30 |
Low | 34.50 |
Bid | 34.20 |
Offer | 35.10 |
Previous close | 35.20 |
Average volume | 130.89 |
---|---|
Shares outstanding | 6.47bn |
Free float | 342.99m |
P/E (TTM) | 25.46 |
Market cap | 270.04bn USD |
EPS (TTM) | 1.62 USD |
Annual div (ADY) | 1.28 EUR |
---|---|
Annual div yield (ADY) | 3.64% |
Div ex-date | Mar 28 2025 |
Div pay-date | May 14 2025 |
Data delayed at least 15 minutes, as of Jul 11 2025 16:20 BST.
More ▼
- Changes to the Roche Enlarged Corporate Executive Committee
- Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
- Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
- Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
- Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
- Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
- New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
- Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
- CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
More ▼